Klazien W. Walstra-Matter
Basel, BS 4056, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Clinical characteristics and therapeutic behavior of breast cancer patients using mistletoe therapy consulting a clinic offering integrative oncology: a registry data analysis.
Journal: BMC complementary medicine and therapies
Published: December 13, 2022
Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion.
Journal: Healthcare (Basel, Switzerland)
Published: July 03, 2021
Cost-effectiveness and resource allocation (CERA) 18 years of evolution: maturity of adulthood and promise beyond tomorrow.
Journal: Cost effectiveness and resource allocation : C/E
Published: April 09, 2020
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Journal: Swiss medical weekly
Published: December 05, 2019
Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Journal: Oral oncology
Published: September 10, 2018
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: May 13, 2018
Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial.
Journal: Annals of surgical oncology
Published: April 04, 2018
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Journal: Breast cancer research and treatment
Published: March 14, 2017
Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.
Journal: Clinical lung cancer
Published: September 13, 2016
A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 02, 2016
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).
Journal: Breast cancer research and treatment
Published: March 30, 2016
Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: January 26, 2016
Last Updated: 09/26/2026